Amicus Therapeutics (NASDAQ:FOLD) has entered into a strategic manufacturing collaboration with Thermo Fisher Scientific (NYSE:TMO).
Thermo Fisher and Amicus will collaborate to develop platform manufacturing capabilities to support the broader portfolio of AAV gene therapy programs.
Current R&D production technologies and capabilities related to the Amicus preclinical and clinical-stage gene therapy programs for CLN6, CLN3, and other potential Batten disease programs are being transferred to and developed at Thermo Fisher’s viral vector services business.
FOLD shares are up 2% premarket.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.